KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Return on Equity (2023 - 2025)

Biocryst Pharmaceuticals' Return on Equity history spans 8 years, with the latest figure at 1.04% for Q4 2025.

  • For Q4 2025, Return on Equity fell 123.0% year-over-year to 1.04%; the TTM value through Dec 2025 reached 1.04%, down 123.0%, while the annual FY2025 figure was 0.89%, 108.0% down from the prior year.
  • Return on Equity reached 1.04% in Q4 2025 per BCRX's latest filing, down from 0.02% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.49% in Q3 2024 to a low of 1.04% in Q4 2025.
  • Average Return on Equity over 3 years is 0.12%, with a median of 0.15% recorded in 2025.
  • Peak YoY movement for Return on Equity: surged 46bps in 2024, then tumbled -123bps in 2025.
  • A 3-year view of Return on Equity shows it stood at 0.39% in 2023, then crashed by -52bps to 0.19% in 2024, then plummeted by -653bps to 1.04% in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Return on Equity are 1.04% (Q4 2025), 0.02% (Q3 2025), and 0.08% (Q2 2025).